What Type of Patients Should Come to China for Treatment?
Postoperative cancer patients should undergo gene therapy to prevent tumor recurrence and metastasis. Patients with cancer in the advanced stages will be assessed based on the ‘score card’. If the patients scored 60 points or more (patients with advanced cancers who can normally carry out daily activities and only sometimes need the help of others = 60 points) and without serious cardio-respiratory obstacles can come for treatment.
“Recombinant Human Ad-p53 Injection (Gendicine) is a broad-spectrum anti-cancer drug which can be used for all solid tumors of the human body”
Gendicine has been clinically administered safely for patients with nasopharyngeal cancer, tongue cancer, laryngeal cancer, lip cancer, liver cancer, lung cancer, breast cancer, ovarian cancer, gastric cancer, thyroid cancer, colorectal cancer, pancreatic cancer, prostate cancer, glioma, peripheral nerve sheath tumors, synovial sarcoma, rhabdomyosarcoma, liposarcoma, cervical cancer, endometrial cancer, malignant melanoma, gallbladder cancer, renal cell carcinoma, parotid carcinoma, ureter cancer, maxillary sinus cancer, pharyngeal cancer, hypopharyngeal carcinoma, bile duct carcinoma, malignant mesothelioma, gingival cancer, mandibular sinus carcinoma, adrenocortical cancer, soft tissue sarcoma, mediastinal cancer, malignant pleural effusion or ascites, abdominal pelvic metastasis, medulloblastoma and malignant fibrous histiocytoma, composing around 50 types of cancers.
“Recombinant Human Ad-p53 Injection” (Gendicine) can be used as sole treatment or as adjuvant therapy. Treating cancer patients with Gendicine alone will achieve great therapeutic effects, but when it is combined with radiotherapy, chemotherapy, intervention therapy, surgery and hyperthermia, Gendicine can greatly enhance the treatment effectiveness and significantly reduce the side effects from radiotherapy and chemotherapy.
Gene therapy can be locally administered as single point or multi-point injection, but Gendicine can also be administered via systemic intravenous infusion. Other treatments such as brachytherapy, cooled radiofrequency ablation, high-intensity focused hyperthermia, interventional perfusion embolization, extracorporeal high-frequency deep hyperthermia needs to be selective in the use of different treatment sites.
Extracorporeal Whole Body Hyperthermia (EWBH) is an advanced treatment from the United States, and it is also the world’s most valuable hyperthermia technique. Under general anesthesia, the blood is pumped out of the body and heated to a temperature which is capable of killing tumor cells. EWBH is a real-time temperature controlled hyperthermia and it is significantly effective against systemic metastasis cancer patients.
Attachment:
Score Card
100 points - can carry out normal activities, asymptomatic and showing no signs of the disease
90 points - can carry out normal activities, showing mild signs and symptoms
80 points - can barely carry out normal activities, showing some signs and symptoms
70 points - can take care of themselves, but unable to maintain normal work or activities
60 points - sometimes need others to help, and most of time they can take care of themselves
50 points - often need the care of others
40 points - cannot take care of themselves and require specialized care
30 points - serious disability
20 points - ill, need for hospitalization and active support
10 points - in critical condition, near death
0 points - death
Department of Oncology
CHC China Shenzhen Heng Sheng Hospital